VERICEL CORP ORD
NASDAQ: VCEL (Vericel Corporation)
Kemas kini terakhir: 4 jam lalu41.18
-1.26 (-2.97%)
| Penutupan Terdahulu | 42.44 |
| Jumlah Dagangan | 533,520 |
| Harga / Pendapatan (P/E Ke hadapan) | 89.29 |
| Harga / Jualan (P/S) | 7.28 |
| Harga / Buku (P/B) | 5.87 |
| Julat 52 Minggu |
| Margin Keuntungan | 1.25% |
| Margin Operasi (TTM) | -24.32% |
| EPS Cair (TTM) | 0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 52.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 33.72% |
| Nisbah Semasa (MRQ) | 5.01 |
| Aliran Tunai Operasi (OCF TTM) | 57.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -22.77 M |
| Pulangan Atas Aset (ROA TTM) | -0.45% |
| Pulangan Atas Ekuiti (ROE TTM) | 1.13% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Vericel Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -0.5 |
| Purata | -2.86 |
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.06% |
| % Dimiliki oleh Institusi | 107.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Congress Asset Management Co | 30 Jun 2026 | 2,916,295 |
| Conestoga Capital Advisors, Llc | 30 Jun 2026 | 2,083,832 |
| Gw&K Investment Management, Llc | 30 Jun 2026 | 1,550,497 |
| Geneva Capital Management Llc | 30 Jun 2026 | 1,339,123 |
| Loomis Sayles & Co L P | 30 Jun 2026 | 1,200,239 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |